A Tosetto1, S Testa2, I Martinelli3, D Poli4, B Cosmi5, C Lodigiani6, W Ageno7, V De Stefano8, A Falanga9, I Nichele1, O Paoletti2, P Bucciarelli3, E Antonucci10, C Legnani5, E Banfi6, F Dentali7, F Bartolomei8, L Barcella9, G Palareti10. 1. Hematology Department, San Bortolo Hospital, Vicenza, Italy. 2. Hemostasis and Thrombosis Center, AO Istituti Ospitalieri di Cremona, Cremona, Italy. 3. Hemophilia and Thrombosis Center, Fondazione Angelo Bianchi Bonomi, IRCCS Ospedale Ca' Granda, Dipartimento di Medicina Interna, Università degli Studi di Milano, Milan, Italy. 4. Thrombosis Center, Dipartimento Oncologico AOU Careggi, Florence, Italy. 5. Department of Angiology and Blood Coagulation, S. Orsola Malpighi University Hospital, Bologna, Italy. 6. Thrombosis and Hemorragic Diseases Unit, IRCCS Humanitas Research Hospital, Milan, Italy. 7. Department of Medicine and Surgery, University of Insubria, Varese, Italy. 8. Institute of Hematology, Catholic University, Rome, Italy. 9. Thrombosis and Hemostasis Center, Department of Immunohematology and Transfusion Medicine, Bergamo, Italy. 10. Fondazione Arianna Anticoagulazione, Bologna, Italy.
Abstract
Essentials Predicting recurrences may guide therapy after unprovoked venous thromboembolism (VTE). We evaluated the DASH score in 827 patients with unprovoked VTE to verify prediction accuracy. A DASH score ≤ 1 had a cumulative recurrence risk at 1 year of 3.6%, as predicted by the model. The DASH score performed better in younger (< 65 years old) subjects. SUMMARY: Background The DASH prediction model has been proposed as a guide to identify patients at low risk of recurrence of venous thromboembolism (VTE), but has never been validated in an independent cohort. Aims To validate the calibration and discrimination of the DASH prediction model, and to evaluate the DASH score in a predefined patient subgroup aged > 65 years. Methods Patients with a proximal unprovoked deep vein thrombosis (DVT) or pulmonary embolism (PE) who received a full course of vitamin K antagonist or direct oral anticoagulant (> 3 months) and had D-dimer measured after treatment withdrawal were eligible. The DASH score was computed on the basis of the D-dimer level after therapy withdrawal and personal characteristics at the time of the event. Recurrent VTE events were symptomatic proximal or distal DVT/PE, and were analyzed with a time-dependent analysis. Observed 12-month and 24-month recurrence rates were compared with recurrence rates predicted by the DASH model. Results We analyzed a total of 827 patients, of whom 100 (12.1%) had an objectively documented recurrence. As compared with the original DASH cohort, there was a greater proportion of subjects with a 'low-risk' (≤ 1) DASH score (66.3% versus 51.6%, P < 0.001). The slope of the observed versus expected cumulative incidence at 2 years was 0.71 (95% confidence interval 0.51-1.45). The c-statistic was lower for subjects aged > 65 years (0.54) than for younger subjects (0.72). Conclusions These results confirm the validity of DASH prediction model, particularly in young subjects. The recurrence risk in elderly patients (> 65 years) was, however, > 5% even in those with the lowest DASH scores.
Essentials Predicting recurrences may guide therapy after unprovoked venous thromboembolism (VTE). We evaluated the DASH score in 827 patients with unprovoked VTE to verify prediction accuracy. A DASH score ≤ 1 had a cumulative recurrence risk at 1 year of 3.6%, as predicted by the model. The DASH score performed better in younger (< 65 years old) subjects. SUMMARY: Background The DASH prediction model has been proposed as a guide to identify patients at low risk of recurrence of venous thromboembolism (VTE), but has never been validated in an independent cohort. Aims To validate the calibration and discrimination of the DASH prediction model, and to evaluate the DASH score in a predefined patient subgroup aged > 65 years. Methods Patients with a proximal unprovoked deep vein thrombosis (DVT) or pulmonary embolism (PE) who received a full course of vitamin K antagonist or direct oral anticoagulant (> 3 months) and had D-dimer measured after treatment withdrawal were eligible. The DASH score was computed on the basis of the D-dimer level after therapy withdrawal and personal characteristics at the time of the event. Recurrent VTE events were symptomatic proximal or distal DVT/PE, and were analyzed with a time-dependent analysis. Observed 12-month and 24-month recurrence rates were compared with recurrence rates predicted by the DASH model. Results We analyzed a total of 827 patients, of whom 100 (12.1%) had an objectively documented recurrence. As compared with the original DASH cohort, there was a greater proportion of subjects with a 'low-risk' (≤ 1) DASH score (66.3% versus 51.6%, P < 0.001). The slope of the observed versus expected cumulative incidence at 2 years was 0.71 (95% confidence interval 0.51-1.45). The c-statistic was lower for subjects aged > 65 years (0.54) than for younger subjects (0.72). Conclusions These results confirm the validity of DASH prediction model, particularly in young subjects. The recurrence risk in elderly patients (> 65 years) was, however, > 5% even in those with the lowest DASH scores.
Authors: Kristen M Sanfilippo; Suhong Luo; Tzu-Fei Wang; Mark Fiala; Martin Schoen; Tanya M Wildes; Joseph Mikhael; Nicole M Kuderer; David C Calverley; Jesse Keller; Theodore Thomas; Kenneth R Carson; Brian F Gage Journal: Am J Hematol Date: 2019-08-19 Impact factor: 10.047
Authors: Jasmijn F Timp; Sigrid K Braekkan; Willem M Lijfering; Astrid van Hylckama Vlieg; John-Bjarne Hansen; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter Journal: PLoS Med Date: 2019-10-11 Impact factor: 11.069
Authors: Gualtiero Palareti; Cristina Legnani; Emilia Antonucci; Benilde Cosmi; Daniela Poli; Sophie Testa; Alberto Tosetto; Walter Ageno; Anna Falanga; Piera Maria Ferrini; Vittorio Pengo; Paolo Prandoni Journal: Intern Emerg Med Date: 2019-11-05 Impact factor: 3.397
Authors: Jasmijn F Timp; Willem M Lijfering; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter Journal: J Thromb Haemost Date: 2019-07-04 Impact factor: 5.824